NLM Digital Collections

Search

Start Over Subjects Humans ✖Remove constraint Subjects: Humans Subjects Treatment Outcome ✖Remove constraint Subjects: Treatment Outcome

11. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 6, 2017
Subject(s):
Comparative Effectiveness Research
Multiple Sclerosis, Chronic Progressive -- drug therapy
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- economics
Antirheumatic Agents -- therapeutic use
Benchmarking
Cost-Benefit Analysis
Immunosuppressive Agents -- adverse effects
Immunosuppressive Agents -- economics
Immunosuppressive Agents -- therapeutic use
Insurance Coverage
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

12. Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 10, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Immunotherapy
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Protein Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Value-Based Purchasing
Humans
United States

13. Controversies in migraine management: a technology assessment : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Weissberg, Jed, author
Shore, Karen K., author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, August 19, 2014
Subject(s):
Analgesics, Opioid -- therapeutic use
Botulinum Toxins, Type A -- therapeutic use
Emergency Medical Services
Magnetic Field Therapy
Migraine Disorders -- drug therapy
Migraine Disorders -- economics
Migraine Disorders -- prevention & control
Migraine Disorders -- therapy
Transcutaneous Electric Nerve Stimulation
Analgesics, Opioid -- adverse effects
Analgesics, Opioid -- economics
Chronic Disease
Cost-Benefit Analysis
Disease Management
Insurance Coverage
Migraine Disorders -- epidemiology
Migraine with Aura -- therapy
Randomized Controlled Trials as Topic
Technology Assessment, Biomedical
Treatment Outcome
Humans
California
United States

15. Indications for and management of inferior vena cava filters

Publication:
[Harrisburg, Pa.] : Pennsylvania Patient Safety Authority, c2011
Subject(s):
Patient Care Management
Pulmonary Embolism -- prevention & control
Vena Cava Filters -- utilization
Venous Thrombosis -- prevention & control
Anticoagulants -- therapeutic use
Device Removal
Pulmonary Embolism -- etiology
Safety
Treatment Outcome
Vena Cava Filters -- adverse effects
Venous Thrombosis -- complications
Humans
United States

16. Timely treatment of stroke symptoms in the emergency department may improve outcomes

Publication:
[Harrisburg, Pa.] : Pennsylvania Patient Safety Authority, c2008
Subject(s):
Brain Ischemia -- drug therapy
Emergency Medical Services -- methods
Fibrinolytic Agents -- therapeutic use
Stroke -- diagnosis
Stroke -- drug therapy
Thrombolytic Therapy -- methods
Tissue Plasminogen Activator -- therapeutic use
Risk Management
Time Factors
Treatment Outcome
Humans
Pennsylvania
United States

17. Sterile water should not be given "freely"

Publication:
[Harrisburg, Pa.] : Pennsylvania Patient Safety Authority, c2008
Subject(s):
Fluid Therapy -- adverse effects
Hypernatremia -- therapy
Infusions, Intravenous -- adverse effects
Water -- adverse effects
Water-Electrolyte Imbalance -- complications
Contraindications
Fluid Therapy
Hypotonic Solutions
Product Packaging
Risk Management
Sodium -- blood
Water -- administration & dosage
Water-Electrolyte Imbalance -- therapy
Medication Errors
Osmolar Concentration
Treatment Outcome
Humans
Pennsylvania
United States

18. Voretigene neparvovec for biallelic RPE65-mediated retinal disease: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, February 14, 2018
Subject(s):
Genetic Therapy
Leber Congenital Amaurosis -- genetics
Leber Congenital Amaurosis -- therapy
Retinal Diseases -- genetics
Retinal Diseases -- therapy
Retinal Pigment Epithelium -- abnormalities
Mutation
Randomized Controlled Trials as Topic
Treatment Outcome
Visual Acuity
Humans
United States

19. Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, March 23, 2018
Subject(s):
Immunotherapy, Adoptive
Leukemia, B-Cell -- drug therapy
Lymphoma, B-Cell -- drug therapy
Lymphoma, Non-Hodgkin -- drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Adult
Child
Clinical Trials as Topic
Clofarabine -- therapeutic use
Cost-Benefit Analysis
Immunotherapy, Adoptive -- adverse effects
Immunotherapy, Adoptive -- economics
Receptors, Chimeric Antigen -- therapeutic use
Treatment Outcome
Humans
United States

20. Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2018
Subject(s):
Antibodies, Bispecific -- therapeutic use
Antibodies, Monoclonal -- therapeutic use
Hemophilia A -- drug therapy
Antibodies, Bispecific -- adverse effects
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Treatment Outcome
Humans
United States